Commentary on the implications of safety and efficacy studies in pediatric patients with administration of human rabies immune globulin (HRIG)?
The FDA strongly encourages rigorous safety and efficacy studies in all age groups for which vaccines and treatments for pervasive and severe diseases are intended. Until recently, there had been no safety and efficacy studies conducted in children for human rabies immune globulins. The publication,...
Main Authors: | Jerry Siegel, Karl Kappeler |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-11-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2022.2054262 |
Similar Items
-
Adherence to guideline recommendations for human rabies immune globulin patient selection, dosing, timing, and anatomical site of administration in rabies postexposure prophylaxis
by: Grace S. Hwang, et al.
Published: (2020-01-01) -
Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: A phase III, randomized, double-blind, non-inferiority trial
by: Xiaoqiang Liu, et al.
Published: (2023-09-01) -
In Vivo Efficacy of SYN023, an Anti-Rabies Monoclonal Antibody Cocktail, in Post-Exposure Prophylaxis Animal Models
by: Tzu-Yuan Chao, et al.
Published: (2020-02-01) -
Time to Revise the WHO Categories for Severe Rabies Virus Exposures–Category IV?
by: Stephen J. Scholand, et al.
Published: (2022-05-01) -
Fatal cases in pediatric patients after post-exposure prophylaxis for rabies: A report of two cases
by: Hekmatollah Khoubfekr, et al.
Published: (2024-01-01)